These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15252271)

  • 1. Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease.
    Voon V; Lang AE
    Clin Neuropharmacol; 2004; 27(2):90-2. PubMed ID: 15252271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.
    Meco G; Bernardi S
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):311-3. PubMed ID: 16919377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of hallucinations and psychosis in Parkinson's disease.
    Eng ML; Welty TE
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):316-30. PubMed ID: 20869621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.
    Aarsland D; Larsen JP; Cummins JL; Laake K
    Arch Neurol; 1999 May; 56(5):595-601. PubMed ID: 10328255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
    Panchal SC; Ondo WG
    Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson's disease psychosis.
    Kulick CV; Montgomery KM; Nirenberg MJ
    Parkinsonism Relat Disord; 2018 Sep; 54():40-45. PubMed ID: 29653909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Psychoses in patients with Parkinson's disease; their frequency, phenomenology, and clinical correlates].
    Kashihara K; Ohno M; Katsu Y
    Rinsho Shinkeigaku; 2005 Jan; 45(1):1-5. PubMed ID: 15714992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report.
    Tagai K; Nagata T; Shinagawa S; Tsuno N; Ozone M; Nakayama K
    Psychogeriatrics; 2013 Jun; 13(2):103-7. PubMed ID: 23909968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Antidepressants on Psychotic Symptoms in Parkinson Disease: A Review of Case Reports and Case Series.
    Sid-Otmane L; Huot P; Panisset M
    Clin Neuropharmacol; 2020; 43(3):61-65. PubMed ID: 32217864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Threatening auditory hallucinations and Cotard syndrome in Parkinson disease.
    Factor SA; Molho ES
    Clin Neuropharmacol; 2004; 27(5):205-7. PubMed ID: 15602098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychiatric comorbidities in patients with Parkinson disease and psychosis.
    Marsh L; Williams JR; Rocco M; Grill S; Munro C; Dawson TM
    Neurology; 2004 Jul; 63(2):293-300. PubMed ID: 15277623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease psychosis 2010: a review article.
    Friedman JH
    Parkinsonism Relat Disord; 2010 Nov; 16(9):553-60. PubMed ID: 20538500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
    Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
    Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hallucinations and the spectrum of psychosis in Parkinson's disease.
    Frei K; Truong DD
    J Neurol Sci; 2017 Mar; 374():56-62. PubMed ID: 28108020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of psychotic symptoms in a community-based Parkinson disease sample.
    Mack J; Rabins P; Anderson K; Goldstein S; Grill S; Hirsch ES; Lehmann S; Little JT; Margolis RL; Palanci J; Pontone G; Weiss H; Williams JR; Marsh L
    Am J Geriatr Psychiatry; 2012 Feb; 20(2):123-32. PubMed ID: 21617521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of the scale for assessment of positive symptoms in Parkinson's disease psychosis.
    Voss TS; Brocht AF; Ravina B
    Mov Disord; 2010 Jan; 25(1):124-5. PubMed ID: 19412941
    [No Abstract]   [Full Text] [Related]  

  • 17. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition.
    Menza M; Marin H; Kaufman K; Mark M; Lauritano M
    J Neuropsychiatry Clin Neurosci; 2004; 16(3):315-9. PubMed ID: 15377738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hallucinations and psychosis in Parkinson's disease.
    Rabey JM
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S105-10. PubMed ID: 20123547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
    Kianirad Y; Simuni T
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emergency treatment of depression complicated by psychosis or agitation.
    Glick RL; Ghaemi SN
    J Clin Psychiatry; 2000; 61 Suppl 14():43-8. PubMed ID: 11154016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.